Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)

P1, N=26, Terminated, National Cancer Institute (NCI) | Completed --> Terminated; Study closed due to low accrual.

P1, N=72, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting

P1, N=72, Not yet recruiting, Merck Sharp & Dohme LLC

P1/2, N=1080, Completed, GlaxoSmithKline | Active, not recruiting --> Completed | Phase classification: P2 --> P1/2

P=N/A, N=392, Active, not recruiting, Xiamen University | Not yet recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025

P4, N=1403, Completed, Columbia University | Active, not recruiting --> Completed

P4, N=360, Recruiting, Boston Medical Center | Trial completion date: Sep 2025 --> Dec 2025

P2, N=85, Not yet recruiting, Centre Oscar Lambret

P1, N=150, Active, not recruiting, Boston Medical Center | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2028 --> Jul 2028

Our research confirms a widespread HR-HPV infection in our population and extends the importance of studies on the molecular prevalence of HPV, particularly in women with normal cytology and apparent good health, in view of the cruel lack of public awareness of HPV infections.

P2, N=180, Not yet recruiting, University of Maryland, Baltimore

P1, N=72, Not yet recruiting, Merck Sharp & Dohme LLC

P4, N=30, Recruiting, Medical College of Wisconsin | N=100 --> 30

In Greece, we observed a high HPV-AF (52.1%) in OPC, approximating the AFs reported for some Northern European countries. HPV+ versus HPV- patients were younger, more frequently with tonsillar tumors, and less frequently at TNM stage IV. Since most patients were infected by ≥1 HPV type targeted by the 9-valent vaccine, the HPV+ OPC burden could be mitigated through a routine HPV gender-neutral vaccination program.

P3, N=1000, Active, not recruiting, Imperial College London | Not yet recruiting --> Active, not recruiting | Trial completion date: Jul 2023 --> Aug 2025 | Trial primary completion date: Jul 2023 --> Aug 2025

For the HGSIL and cancer samples, 88% of the samples had full HPV genotype coverage with the 9-valent HPV vaccine. This study highlights a presence of HPV that will not be protected by vaccination in a high-risk population.

P=N/A, N=610, Recruiting, University of Alabama at Birmingham | Not yet recruiting --> Recruiting

P4, N=100000, Not yet recruiting, Rwanda Biomedical Centre

P3, N=1059, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jan 2025 --> Aug 2025 | Trial primary completion date: Jan 2025 --> Dec 2023

P4, N=158, Active, not recruiting, University Hospital Virgen de las Nieves | Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Jul 2022 --> Sep 2024

In total, 95.2% of HPV-driven HNC were attributed to HPV genotypes included in the 9-valent HPV vaccine being HPV16 the most prominent genotype. These results suggest that an epidemiologic shift is happening in Japan, with a decrease in smoking and alcohol use and an increase in HPV-driven HNC. The increasing trend of HPV-driven HNC in Japan highlights the need for preventive strategies to mitigate the rise of HPV-driven HNC.

P4, N=750, Not yet recruiting, Massachusetts General Hospital

P4, N=48, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025

P3, N=700, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting

P3, N=312, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed

P1, N=33, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2026 --> Jun 2027

A higher regression rate than expected was observed in the surveillance arm of this prospective trial. Future clinical trials with imiquimod targeting CIN3 patients are warranted.

P=N/A, N=610, Not yet recruiting, University of Alabama at Birmingham | Initiation date: Mar 2024 --> Sep 2024

P4, N=360, Recruiting, Boston Medical Center | Trial completion date: Mar 2025 --> Sep 2025 | Trial primary completion date: Mar 2024 --> Sep 2024

P2/3, N=120, Recruiting, Western Institute for Veterans Research | Not yet recruiting --> Recruiting

P4, N=120, Recruiting, Talia Sainz Costa | Not yet recruiting --> Recruiting

P4, N=757, Active, not recruiting, The University of Texas Medical Branch, Galveston | Recruiting --> Active, not recruiting | Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Feb 2024 --> Mar 2025

P2, N=52, Active, not recruiting, National Cancer Institute (NCI) | N=180 --> 52 | Trial completion date: Dec 2023 --> Mar 2025

P2, N=201, Active, not recruiting, National Cancer Institute (NCI) | Phase classification: P2a --> P2 | Trial completion date: Feb 2024 --> Feb 2025

P4, N=1403, Active, not recruiting, Columbia University | Trial completion date: Oct 2023 --> Sep 2024

P4, N=100, Recruiting, Medical College of Wisconsin | Phase classification: P=N/A --> P4

P4, N=97, Active, not recruiting, Fred Hutchinson Cancer Center | Recruiting --> Active, not recruiting

P=N/A, N=610, Not yet recruiting, University of Alabama at Birmingham

P3, N=536, Active, not recruiting, AIDS Malignancy Consortium | Trial primary completion date: Dec 2025 --> Dec 2024

P3, N=1260, Active, not recruiting, Beijing Health Guard Biotechnology, Inc | Recruiting --> Active, not recruiting

P1, N=33, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Nov 2023 --> Apr 2024 | Trial primary completion date: Nov 2025 --> Apr 2026

P3, N=1260, Recruiting, Beijing Health Guard Biotechnology, Inc